<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597181</url>
  </required_header>
  <id_info>
    <org_study_id>0710-28</org_study_id>
    <nct_id>NCT00597181</nct_id>
  </id_info>
  <brief_title>A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy</brief_title>
  <acronym>Optonol</acronym>
  <official_title>A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optonol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The less invasive nature of the Ex-Press Mini shunt with mitomycin C induces less&#xD;
      post-operative inflammation than trabeculectomy with mitomycin c.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to quantify the degree of post-operative inflammation in eyes&#xD;
      which have undergone either trabeculectomy filtering surgery or Ex-Press mini shunt&#xD;
      insertion. Early intraocular pressure control and postoperative complications will also be&#xD;
      noted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Patient population limited&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous humor flare</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aqueous humor cell</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy with mitomycin c</intervention_name>
    <description>mitomycin c 0.2 mg/cc for 2 minutes</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ex-Press mini shunt with mitomycin c</intervention_name>
    <description>mitomycin c 0.2 mg/cc for 2 minutes</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects must:&#xD;
&#xD;
          1. Be willing and able to provide written Informed Consent.&#xD;
&#xD;
          2. Be able and willing to follow instructions on the use of post- operative medication&#xD;
             and likely to complete the entire course of the study.&#xD;
&#xD;
          3. Be male or female of any race at least 18 years of age.&#xD;
&#xD;
          4. Have medically uncontrolled glaucoma for which they have elected to undergo surgery.&#xD;
&#xD;
          5. Diagnosed with primary open angle glaucoma, pigmentary or pseudoexfoliation glaucoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No subject may:&#xD;
&#xD;
          1. Have any contraindication to intraocular surgery.&#xD;
&#xD;
          2. Diagnosed with: primary angle closure glaucoma, normal tension glaucoma, secondary&#xD;
             glaucoma, neovascular glaucoma.&#xD;
&#xD;
          3. Have any active ocular disease other than glaucoma that would interfere with study&#xD;
             parameters (such as: uveitis, ocular infection, or severe dry eye). Subjects with mild&#xD;
             chronic blepharitis, age-related macular degeneration and background diabetic&#xD;
             retinopathy may be enrolled at the discretion of the investigator.&#xD;
&#xD;
          4. Have laser ALT or SLT within the past 3 months or cataract surgery within the last six&#xD;
             months.&#xD;
&#xD;
          5. Require use of ocular NSAID or systemic steroids.&#xD;
&#xD;
          6. Have known allergy or sensitivity to mitomycin C&#xD;
&#xD;
          7. Have corneal abnormalities that would interfere with the ability to obtain an adequate&#xD;
             laser flare measurement.&#xD;
&#xD;
          8. Be concurrently enrolled in an investigational drug or device study or participation&#xD;
             within the last 30 days in any investigational drug or device study.&#xD;
&#xD;
          9. Be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not&#xD;
             using a reliable form of contraception (a woman is considered of childbearing&#xD;
             potential unless she is postmenopausal, has had a uterus and/or both ovaries removed,&#xD;
             or has had a bilateral tubal ligation).&#xD;
&#xD;
         10. Have a situation or condition that in the investigator's opinion may put the subject&#xD;
             at significant risk, may confound the study results, or may interfere significantly&#xD;
             with participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis B Cantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IU Eye at Carmel</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hille K, Hans J, Manderscheid T, Spang S, Ruprecht KW. [Laser flare in combined cataract and glaucoma surgery]. Ophthalmologe. 2001 Jan;98(1):47-53. German.</citation>
    <PMID>11220271</PMID>
  </reference>
  <reference>
    <citation>Maris PJ Jr, Ishida K, Netland PA. Comparison of trabeculectomy with Ex-PRESS miniature glaucoma device implanted under scleral flap. J Glaucoma. 2007 Jan;16(1):14-9.</citation>
    <PMID>17224744</PMID>
  </reference>
  <reference>
    <citation>Shah SM, Spalton DJ, Allen RJ, Smith SE. A comparison of the laser flare cell meter and fluorophotometry in assessment of the blood-aqueous barrier. Invest Ophthalmol Vis Sci. 1993 Oct;34(11):3124-30.</citation>
    <PMID>8407220</PMID>
  </reference>
  <reference>
    <citation>Dahan E, Carmichael TR. Implantation of a miniature glaucoma device under a scleral flap. J Glaucoma. 2005 Apr;14(2):98-102.</citation>
    <PMID>15741808</PMID>
  </reference>
  <reference>
    <citation>Shields, MB Textbook of Glaucoma. Fourth Edition; Williams &amp; Wilkins, Baltimore, 1998.</citation>
  </reference>
  <reference>
    <citation>Guyer DR, Yannuzzi LA, Chang S, Shields JA, Green WR Retina-Vitreous-Macula. W.B. Saunders Company, Philadelphia, 1999.</citation>
  </reference>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Louis B. Cantor, M.D.</name_title>
    <organization>Indiana University</organization>
  </responsible_party>
  <keyword>Inflammatory response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

